Literature DB >> 21968508

Type 2 idiopathic macular telangiectasia.

Dhananjay Shukla1, Shashank R Gupta, Nithya Neelakantan, Sachin Tiwari, Sumi Gupta, Aditi R Patwardhan, Thayyil B Soubhya.   

Abstract

PURPOSE: To describe the natural course of Type 2 idiopathic macular telangiectasia in terms of visual outcomes, causes of visual loss, and incidence of subretinal neovascular membranes (SRNV).
METHODS: This retrospective observational case series consisted of chart review of 104 outpatients (203 eyes; 66 women, 38 men) who were diagnosed to have Type 2 idiopathic macular telangiectasia by clinical examination and fluorescein angiography between January 2000 and December 2008. Visual and anatomic outcomes were analyzed during a minimum follow-up of 1 year.
RESULTS: The mean age of the patients was 57 years (range, 40-74 years). Nineteen eyes (18 patients) presented with SRNV; the number increased to 29 eyes (14%; 23 patients) by the final visit (mean follow-up, 31 months). Diabetes was common (59%) though retinopathy was initially absent or mild to moderate in 99% patients. Mean logarithm of the minimum angle of resolution best-corrected visual acuity declined from 0.35 to 0.43 by the last visit (P < 0.0001) overall; final mean logarithm of the minimum angle of resolution best-corrected visual acuity was 0.61 (20/80) in the eyes with SRNV and 0.40 (20/50) in eyes without SRNV. The latter group started with better best-corrected visual acuity than SRNV group and remained better at 1-year, 2-year, and final follow-ups (P ≤ 0.0002). Overall, 30 eyes (15%; 24 patients) lost ≥ 2 Snellen lines, the main causes being SRNV and intraretinal pigment migration. Of 128 eyes (including SRNV) with best-corrected visual acuity ≥ 20/40 at baseline, 98 (77%) retained stable visual status; 74 (71%) patients retained best-corrected visual acuity of 20/40 or better at least in 1 eye.
CONCLUSION: Over a follow-up of approximately 3 years, most eyes with Type 2 idiopathic macular telangiectasia starting with good vision were found to retain status quo; sight-threatening complications developed in a minority of eyes; most patients retained good vision at least in 1 eye.

Entities:  

Mesh:

Year:  2012        PMID: 21968508     DOI: 10.1097/IAE.0b013e31822091b0

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  7 in total

1.  Diagnosis of subretinal neovascularization associated with idiopathic juxtafoveal retinal telangiectasia - fluorescein angiography versus spectral-domain optical coherence tomography.

Authors:  Jay Chhablani; Kopal Mithal; Harsha Rao; Raja Narayanan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-10-23       Impact factor: 3.117

2.  Co-existing retinal pathologies: Diagnostic challenges in diabetic retinopathy.

Authors:  Aniruddha Agarwal
Journal:  Indian J Ophthalmol       Date:  2021-11       Impact factor: 1.848

3.  Long-term course in type 2 idiopathic macular telangiectasia.

Authors:  Tobias Meyer-ter-Vehn; Sina Herzog; Marc Schargus; Winfried Göbel; Rainer Guthoff
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-04-25       Impact factor: 3.117

4.  Long term follow-up of visual acuity and incidence of subretinal neovascularization in Mactel Type 2 in 82 Eyes.

Authors:  Kerul Marsonia; Kedarisetti Kiran Chandra; M Hasnat Ali; Jay Chhablani; Raja Narayanan
Journal:  Semin Ophthalmol       Date:  2021-05-23       Impact factor: 2.246

5.  Idiopathic macular telangiectasis type 2 and co-existent diabetic retinopathy.

Authors:  Mahima Jhingan; Kerul Marsonia; Dhananjay Shukla; Philip J Rosenfeld; Jay Chhablani
Journal:  Int J Retina Vitreous       Date:  2017-12-25

Review 6.  Clinical applications of optical coherence tomography in the posterior pole: the 2011 José Manuel Espino Lecture - Part II.

Authors:  J Fernando Arevalo; Andres F Lasave; Juan D Arias; Martin A Serrano; Fernando A Arevalo
Journal:  Clin Ophthalmol       Date:  2013-11-08

7.  Risk factors in patients with macular telangiectasia 2A in an Asian population: A case-control study.

Authors:  Anna Elias; Mahesh Gopalakrishnan; Giridhar Anantharaman
Journal:  Indian J Ophthalmol       Date:  2017-09       Impact factor: 1.848

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.